

Gabriele Missale

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/809530/publications.pdf>

Version: 2024-02-01

128
papers

11,819
citations

30070

54
h-index

26613

107
g-index

129
all docs

129
docs citations

129
times ranked

11203
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1789-1796.	1.6	940
2	Characterization of Hepatitis B Virus (HBV)-Specific T-Cell Dysfunction in Chronic HBV Infection. <i>Journal of Virology</i> , 2007, 81, 4215-4225.	3.4	801
3	Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.. <i>Journal of Clinical Investigation</i> , 1996, 98, 706-714.	8.2	617
4	PD-1 Expression in Acute Hepatitis C Virus (HCV) Infection Is Associated with HCV-Specific CD8 Exhaustion. <i>Journal of Virology</i> , 2006, 80, 11398-11403.	3.4	521
5	Antiviral Intrahepatic T-Cell Responses Can Be Restored by Blocking Programmed Death-1 Pathway in Chronic Hepatitis B. <i>Gastroenterology</i> , 2010, 138, 682-693.e4.	1.3	416
6	Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. <i>Gastroenterology</i> , 2004, 126, 102-110.	1.3	389
7	Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen.. <i>Journal of Experimental Medicine</i> , 1991, 174, 1565-1570.	8.5	371
8	Restored Function of HBV-Specific T Cells After Long-term Effective Therapy With Nucleos(t)ide Analogues. <i>Gastroenterology</i> , 2012, 143, 963-973.e9.	1.3	308
9	Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections. <i>Gastroenterology</i> , 1997, 112, 193-199.	1.3	291
10	Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. <i>Hepatology</i> , 2007, 45, 588-601.	7.3	266
11	Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. <i>Gut</i> , 2009, 58, 974-982.	12.1	254
12	Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B. <i>Nature Medicine</i> , 2017, 23, 327-336.	30.7	251
13	HLA-A31- and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis.. <i>Journal of Experimental Medicine</i> , 1993, 177, 751-762.	8.5	238
14	Radiofrequency Thermal Ablation of Hepatocellular Carcinoma Liver Nodules Can Activate and Enhance Tumor-Specific T-Cell Responses. <i>Cancer Research</i> , 2006, 66, 1139-1146.	0.9	236
15	Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. <i>Journal of Hepatology</i> , 2003, 39, 595-605.	3.7	229
16	Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen.. <i>Journal of Clinical Investigation</i> , 1991, 88, 214-222.	8.2	220
17	Interferon (IFN)-Inducible Protein 10: Association with Histological Results, Viral Kinetics, and Outcome during Treatment with Pegylated IFN-2a and Ribavirin for Chronic Hepatitis C Virus Infection. <i>Journal of Infectious Diseases</i> , 2006, 194, 895-903.	4.0	201
18	IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. <i>Hepatology</i> , 2006, 44, 1617-1625.	7.3	193

#	ARTICLE	IF	CITATIONS
19	Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study. <i>Journal of Hepatology</i> , 2015, 62, 617-624.	3.7	184
20	Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. <i>Hepatology</i> , 2006, 44, 126-139.	7.3	176
21	Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein. <i>Journal of Virology</i> , 1993, 67, 2376-2380.	3.4	171
22	Virus-Specific CD8+ Lymphocytes Share the Same Effector-Memory Phenotype but Exhibit Functional Differences in Acute Hepatitis B and C. <i>Journal of Virology</i> , 2002, 76, 12423-12434.	3.4	168
23	Activation of Natural Killer Cells During Acute Infection With Hepatitis C Virus. <i>Gastroenterology</i> , 2010, 138, 1536-1545.	1.3	162
24	Radiofrequency Thermal Ablation for Hepatocellular Carcinoma Stimulates Autologous NK-Cell Response. <i>Gastroenterology</i> , 2010, 138, 1931-1942.e2.	1.3	154
25	Conserved hepatitis C virus sequences are highly immunogenic for CD4+ T cells: Implications for vaccine development. <i>Hepatology</i> , 1999, 30, 1088-1098.	7.3	150
26	Heterologous T cell immunity in severe hepatitis C virus infection. <i>Journal of Experimental Medicine</i> , 2005, 201, 675-680.	8.5	134
27	Response Prediction in Chronic Hepatitis C by Assessment of IP-10 and IL28B-Related Single Nucleotide Polymorphisms. <i>PLoS ONE</i> , 2011, 6, e17232.	2.5	131
28	Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target. <i>Blood</i> , 2016, 128, 667-679.	1.4	128
29	The Characteristics of the Cell-Mediated Immune Response Identify Different Profiles of Occult Hepatitis B Virus Infection. <i>Gastroenterology</i> , 2008, 134, 1470-1481.	1.3	115
30	Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: Effect of viremia levels and antiviral treatment. <i>Journal of Hepatology</i> , 2008, 48, 548-558.	3.7	113
31	Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 61, 333-341.	3.7	110
32	Combined Blockade of Programmed Death-1 and Activation of CD137 Increase Responses of Human Liver T Cells Against HBV, But Not HCV. <i>Gastroenterology</i> , 2012, 143, 1576-1585.e4.	1.3	106
33	IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. <i>Journal of Hepatology</i> , 2011, 55, 980-988.	3.7	97
34	Pathogenetic Mechanisms of T Cell Dysfunction in Chronic HBV Infection and Related Therapeutic Approaches. <i>Frontiers in Immunology</i> , 2020, 11, 849.	4.8	79
35	The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC. <i>Lung Cancer</i> , 2019, 127, 153-163.	2.0	77
36	Peginterferon- α 2 does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis. <i>Journal of Hepatology</i> , 2012, 56, 1239-1246.	3.7	75

#	ARTICLE	IF	CITATIONS
37	Natural killer cell phenotype modulation and natural killer/Tâ€cell interplay in nucleos(t)ide analogueâ€treated hepatitis e antigenâ€negative patients with chronic hepatitis B. <i>Hepatology</i> , 2015, 62, 1697-1709.	7.3	73
38	Increased Immunostimulatory Activity Conferred to Antigen-presenting Cells by Exposure to Antigen Extract From Hepatocellular Carcinoma After Radiofrequency Thermal Ablation. <i>Journal of Immunotherapy</i> , 2008, 31, 271-282.	2.4	72
39	Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. <i>Journal of Viral Hepatitis</i> , 2007, 14, 29-35.	2.0	70
40	A metaâ€analysis of single <scp>HCV</scp>â€untreated arm of studies evaluating outcomes after curative treatments of <scp>HCV</scp>â€related hepatocellular carcinoma. <i>Liver International</i> , 2017, 37, 1157-1166.	3.9	70
41	Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of <scp>HCV</scp> eradication does not depend on the use of interferon. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 160-168.	3.7	70
42	The changing scenario of hepatocellular carcinoma in Italy: an update. <i>Liver International</i> , 2021, 41, 585-597.	3.9	69
43	Intrahepatic and circulating HLA class II-restricted, hepatitis C virus-specific T cells: Functional characterization in patients with chronic hepatitis C. <i>Hepatology</i> , 2002, 35, 1225-1236.	7.3	68
44	Immunopathogenesis of hepatitis B. <i>Journal of Hepatology</i> , 2003, 39, 36-42.	3.7	67
45	The evolutionary scenario of hepatocellular carcinoma in Italy: an update. <i>Liver International</i> , 2017, 37, 259-270.	3.9	67
46	Immune landscape of hepatocellular carcinoma microenvironment: Implications for prognosis and therapeutic applications. <i>Liver International</i> , 2019, 39, 1608-1621.	3.9	67
47	Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+cells in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2004, 40, 102-109.	3.7	66
48	Oral lichen planus pathogenesis: A role for the HCV-specific cellular immune response. <i>Hepatology</i> , 2002, 36, 1446-1452.	7.3	66
49	Antibody responses to hepatitis C virus hypervariable region 1: Evidence for cross-reactivity and immune-mediated sequence variation. <i>Hepatology</i> , 1999, 30, 537-545.	7.3	62
50	Immunological and Molecular Correlates of Disease Recurrence after Liver Resection for Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2012, 7, e32493.	2.5	61
51	Comparison between alcoholâ€and hepatitis C virusâ€related hepatocellular carcinoma: clinical presentation, treatment and outcome. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 385-399.	3.7	59
52	Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2016, 111, 70-77.	0.4	59
53	Acute phase HBV-specific T cell responses associated with HBV persistence after HBV/HCV coinfection. <i>Hepatology</i> , 2005, 41, 826-831.	7.3	57
54	The Impairment of CD8 Responses Limits the Selection of Escape Mutations in Acute Hepatitis C Virus Infection. <i>Journal of Immunology</i> , 2005, 175, 7519-7529.	0.8	57

#	ARTICLE	IF	CITATIONS
55	HCV-Specific T-Cell Response in Relation to Viral Kinetics and Treatment Outcome (DITTO-HCV Project). <i>Gastroenterology</i> , 2007, 133, 1132-1143.	1.3	57
56	Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002–2033: the ITA.LI.CA database. <i>Gut</i> , 2023, 72, 141-152.	12.1	57
57	Practice guidelines for the treatment of hepatitis C: Recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. <i>Digestive and Liver Disease</i> , 2010, 42, 81-91.	0.9	56
58	Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: Implications for its clinical use. <i>Cancer</i> , 2014, 120, 2150-2157.	4.1	56
59	Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts. <i>British Journal of Cancer</i> , 2014, 111, 1159-1167.	6.4	55
60	Oral lichen planus pathogenesis: A role for the HCV-specific cellular immune response. <i>Hepatology</i> , 2002, 36, 1446-1452.	7.3	53
61	Combination of radiofrequency ablation and immunotherapy. <i>Frontiers in Bioscience - Landmark</i> , 2008, 13, 369.	3.0	53
62	Lack of full CD8 functional restoration after antiviral treatment for acute and chronic hepatitis C virus infection. <i>Gut</i> , 2012, 61, 1076-1084.	12.1	51
63	The role of anti-core antibody response in the detection of occult hepatitis B virus infection. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 23-29.	2.3	49
64	Expression of pERK and VEGFR β in advanced hepatocellular carcinoma and resistance to sorafenib treatment. <i>Liver International</i> , 2015, 35, 2001-2008.	3.9	49
65	HLA and Killer Immunoglobulin-like Receptor Genes as Outcome Predictors of Hepatitis C Virus-Related Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 5465-5473.	7.0	46
66	Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. <i>Liver International</i> , 2017, 37, 423-433.	3.9	46
67	L-Asparaginase and Inhibitors of Glutamine Synthetase Disclose Glutamine Addiction of β -Catenin-Mutated Human Hepatocellular Carcinoma Cells. <i>Current Cancer Drug Targets</i> , 2011, 11, 929-943.	1.6	45
68	Targeting p53 and histone methyltransferases restores exhausted CD8+ T cells in HCV infection. <i>Nature Communications</i> , 2020, 11, 604.	12.8	44
69	HBV Immune-Therapy: From Molecular Mechanisms to Clinical Applications. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2754.	4.1	43
70	The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study. <i>Liver International</i> , 2019, 39, 1478-1489.	3.9	41
71	The Good and the Bad of Natural Killer Cells in Virus Control: Perspective for Anti-HBV Therapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5080.	4.1	39
72	Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 859-871.	1.7	38

#	ARTICLE	IF	CITATIONS
73	Natural killer cells phenotypic characterization as an outcome predictor of HCV-linked HCC after curative treatments. <i>Oncolmmunology</i> , 2016, 5, e1154249.	4.6	37
74	Treatment optimization and prediction of HCV clearance in patients with acute HCV infection. <i>Journal of Hepatology</i> , 2013, 59, 221-228.	3.7	34
75	Functional reconstitution of HBV-specific CD8 T cells by inÂvitro polyphenol treatment in chronic hepatitis B. <i>Journal of Hepatology</i> , 2021, 74, 783-793.	3.7	33
76	A Simplified SARS-CoV-2 Pseudovirus Neutralization Assay. <i>Vaccines</i> , 2021, 9, 389.	4.4	30
77	Intratumor Regulatory Noncytotoxic NK Cells in Patients with Hepatocellular Carcinoma. <i>Cells</i> , 2021, 10, 614.	4.1	24
78	Focal Adhesion Kinase (FAK) Mediates the Induction of Pro-Oncogenic and Fibrogenic Phenotypes in Hepatitis C Virus (HCV)-Infected Cells. <i>PLoS ONE</i> , 2012, 7, e44147.	2.5	23
79	Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy. <i>Pharmacogenomics Journal</i> , 2014, 14, 14-19.	2.0	21
80	Immune Gene Expression Profile in Hepatocellular Carcinoma and Surrounding Tissue Predicts Time to Tumor Recurrence. <i>Liver Cancer</i> , 2018, 7, 277-294.	7.7	21
81	Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications. <i>Cancers</i> , 2021, 13, 1673.	3.7	21
82	Role of viral and host factors in HCV persistence: which lesson for therapeutic and preventive strategies?. <i>Digestive and Liver Disease</i> , 2004, 36, 703-711.	0.9	20
83	Years of life that could be saved from prevention of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 814-824.	3.7	20
84	Are Anti-TNF-Î± Agents Safe for Treating Psoriasis in Hepatitis C Virus Patients with Advanced Liver Disease? Case Reports and Review of the Literature. <i>Dermatology</i> , 2016, 232, 102-106.	2.1	19
85	Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines. <i>Frontiers in Oncology</i> , 2020, 10, 563249.	2.8	18
86	Pattern of macrovascular invasion in hepatocellular carcinoma. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13542.	3.4	18
87	Is there a role for immunotherapy in hepatocellular carcinoma?. <i>Digestive and Liver Disease</i> , 2006, 38, 221-225.	0.9	17
88	Percutaneous Ultrasound-Guided Radiofrequency Ablation of an Allograft Renal Cell Carcinoma: A Case Report. <i>Transplantation Proceedings</i> , 2011, 43, 3997-3999.	0.6	16
89	Energy metabolism and cell motility defect in NK-cells from patients with hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1589-1603.	4.2	16
90	Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 149, 102927.	4.4	15

#	ARTICLE	IF	CITATIONS
91	Infection of Circulating and Liver Infiltrating T Cells by Hepatitis C Virus of Different Subtypes. <i>Viral Immunology</i> , 1995, 8, 63-73.	1.3	14
92	Parenteral exposure to high HIV viremia leads to virus-specific T cell priming without evidence of infection. <i>European Journal of Immunology</i> , 2004, 34, 3208-3215.	2.9	14
93	Hepatitis C virus and alcohol: Same mitotic targets but different signaling pathways. <i>Journal of Hepatology</i> , 2011, 54, 956-963.	3.7	14
94	T cell regulation in HBV-related chronic liver disease. <i>Journal of Hepatology</i> , 2017, 66, 1096-1098.	3.7	14
95	Antiviral CD8-mediated responses in chronic HCV carriers with HBV superinfection. <i>Hepatology</i> , 2004, 40, 289-299.	7.3	13
96	Etanercept in the treatment of psoriasis and psoriatic arthritis with concomitant hepatitis C virus infection: clinical and virological study in three patients. <i>European Journal of Dermatology</i> , 2011, 21, 564-567.	0.6	13
97	Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA, LI, CA centres. <i>Liver International</i> , 2013, 33, 1420-1427.	3.9	13
98	KIR/HLA immunogenetic background influences the evolution of hepatocellular carcinoma. <i>Oncotarget</i> , 2013, 2, e26622.	4.6	13
99	Impact of Soluble CD26 on Treatment Outcome and Hepatitis C Virus-Specific T Cells in Chronic Hepatitis C Virus Genotype 1 Infection. <i>PLoS ONE</i> , 2013, 8, e56991.	2.5	12
100	Unraveling the Multifaceted Nature of CD8 T Cell Exhaustion Provides the Molecular Basis for Therapeutic T Cell Reconstitution in Chronic Hepatitis B and C. <i>Cells</i> , 2021, 10, 2563.	4.1	12
101	Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: a pilot case-control study. <i>Oncotarget</i> , 2018, 9, 17483-17490.	1.8	12
102	Human leukocyte antigen class I-independent pathways may contribute to hepatitis B virus-induced liver disease after liver transplantation. <i>Hepatology</i> , 1993, 18, 491-496.	7.3	11
103	Who is more likely to respond to dual treatment with pegylated interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis. <i>Journal of Viral Hepatitis</i> , 2013, 20, 790-800.	2.0	11
104	Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor. <i>Liver Transplantation</i> , 2015, 21, 1250-1258.	2.4	10
105	Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis. <i>Pharmacogenomics Journal</i> , 2016, 16, 18-29.	2.0	10
106	Monofocal hepatocellular carcinoma: How much does size matter?. <i>Liver International</i> , 2021, 41, 396-407.	3.9	10
107	Metabolic regulation of the HBV-specific T cell function. <i>Antiviral Research</i> , 2021, 185, 104989.	4.1	9
108	Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation <i>in vitro</i> . <i>Oncotarget</i> , 2017, 8, 15704-15715.	1.8	9

#	ARTICLE	IF	CITATIONS
109	Integrated prognostication of intrahepatic cholangiocarcinoma by contrast-enhanced computed tomography: the adjunct yield of radiomics. <i>Abdominal Radiology</i> , 2021, 46, 4689-4700.	2.1	8
110	Antigen Load and T Cell Function: A Challenging Interaction in HBV Infection. <i>Biomedicines</i> , 2022, 10, 1224.	3.2	6
111	Comparative pathogenesis of HBV and HCV. <i>Virus Research</i> , 2001, 82, 19-23.	2.2	5
112	Intrahepatic <sc>mRNA</sc> levels of SOCS1 and SOCS3 are associated with cirrhosis but do not predict virological response to therapy in chronic hepatitis C. <i>Liver International</i> , 2013, 33, 94-103.	3.9	5
113	AISF position paper on HCV in immunocompromised patients. <i>Digestive and Liver Disease</i> , 2019, 51, 10-23.	0.9	5
114	Hepatocellular cancer therapy in patients with HIV infection: Disparities in cancer care, trials enrolment, and cancer-related research. <i>Translational Oncology</i> , 2021, 14, 101153.	3.7	5
115	Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival. <i>Digestive and Liver Disease</i> , 2022, 54, 927-936.	0.9	4
116	Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment. <i>European Journal of Cancer</i> , 2021, 158, 133-143.	2.8	4
117	Gene expression analysis during acute hepatitis C virus infection associates dendritic cell activation with viral clearance. <i>Journal of Medical Virology</i> , 2016, 88, 843-851.	5.0	3
118	Clinico-Immunological Profile of a 67-Year-Old Woman Affected by HER2-Positive Breast Cancer and Autoimmune Dermatomyositis. <i>Frontiers in Oncology</i> , 2020, 10, 192.	2.8	3
119	Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2022, 54, 1215-1221.	0.9	3
120	Early intrahepatic CD8 responses in HBV pathogenesis: A new piece of the puzzle. <i>Journal of Hepatology</i> , 2006, 45, 169-171.	3.7	2
121	Recalibrating survival prediction among patients receiving transarterial chemoembolization for hepatocellular carcinoma. <i>Liver Cancer International</i> , 2021, 2, 45-53.	1.3	2
122	Targeting Stress Sensor Kinases in Hepatocellular Carcinoma-Infiltrating Human NK Cells as a Novel Immunotherapeutic Strategy for Liver Cancer. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	2
123	Erratum to "Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B". <i>Journal of Hepatology</i> , 2004, 40, 1053-1054.	3.7	1
124	Vascular liver injury mimicking an intrahepatic cholangiocarcinoma in a COVID-19 patient. <i>Journal of Medical Virology</i> , 2021, 93, 1940-1942.	5.0	1
125	Different proliferative and cytolytic function of memory HBV and HCV-specific cytotoxic T cells in acute hepatitis B and C. <i>Journal of Hepatology</i> , 2002, 36, 24.	3.7	0
126	Corrigendum to "Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: Effect of viremia levels and antiviral treatment". <i>J Hepatol</i> 48 (2008) 548-558]. <i>Journal of Hepatology</i> , 2008, 49, 483.	3.7	0

#	ARTICLE	IF	CITATIONS
127	Natural Killer Cells in Hepatocellular Carcinoma: Anti-Tumor Effect and Therapeutic Potential. , 2017, , 19-38.		0
128	Neoplastic macrovascular invasion represents an independent risk factor for dismal survival in sorafenib treatment for hepatocellular carcinoma. Hepatoma Research, 2017, 3, 260.	1.5	0